Bioventix (BVXP) AI Stock Analysis

• Market Cap: £96.66M
• Dividend Yield: 8.33%
• Average Volume (3M): 7.85K
• Price to Earnings (P/E): 12.7
• Beta (1Y): 0.53
• Revenue Growth: -3.61%
• EPS Growth: -6.35%
• Country: UK
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.72
• Shares Outstanding: 5,224,860
• 10 Day Avg. Volume: 9,152
• 30 Day Avg. Volume: 7,851
• PEG Ratio: -2.93
• Price to Book (P/B): 12.43
• Price to Sales (P/S): 10.95
• P/FCF Ratio: 20.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 75 Outperform
• Price Target: 2,025.00p ▲(12.50% Upside)

The score is driven primarily by very strong financial quality (high profitability, strong cash conversion, and no debt). This is tempered by weak technicals (price below key moving averages with negative MACD) and signs of slowing operating momentum in 2025. Valuation and dividend yield are supportive, while corporate updates are mixed (insider buying versus revenue/profit pressure).

Positive Factors

Strong Financial Position

Bioventix's debt-free balance sheet and strong profitability ensure financial stability, enabling sustained investment in R&D and strategic growth.

Cash Flow Management

Efficient cash flow management supports ongoing operations and strategic initiatives, ensuring the company can capitalize on growth opportunities.

CEO Stake Increase

The CEO's increased stake reflects confidence in the company's future, aligning management interests with shareholders and potentially enhancing strategic execution.

Negative Factors

Revenue Growth Slowdown

Minimal revenue growth may indicate challenges in expanding market share or product adoption, potentially impacting long-term financial performance.

Profit Decline

Decreased profitability due to higher R&D expenses could strain financial resources, though it may also lead to future product innovations.

EPS Growth Decline

A decline in EPS growth suggests potential challenges in maintaining earnings momentum, which could affect investor confidence and valuation.

Bioventix Business Overview & Revenue Model

Company Description

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.

How the Company Makes Money

Bioventix makes money by licensing its proprietary antibodies to global diagnostics companies that incorporate them into their own diagnostic testing systems. The company generates revenue through upfront fees, milestone payments, and royalties based on the sales of diagnostic products that utilize its antibodies. These revenue streams are bolstered by long-term relationships with major diagnostics companies and continuous development of novel antibodies to meet emerging market needs. Bioventix's focus on high-quality, niche antibody products helps secure a competitive position and steady demand within the diagnostics industry.

Bioventix Financial Statement Overview

Summary

Financials are very strong: elite profitability and cash conversion, with a conservative balance sheet (zero debt). The main offset is a clear recent slowdown, with 2025 showing declines in revenue and free cash flow versus 2024.

Income Statement

Bioventix shows exceptionally strong profitability, with consistently very high gross and operating margins and net profit margins holding near ~58–70% across recent years. Revenue expanded steadily from 2020–2024, but the latest year (2025) shows a modest revenue decline (about -4%), alongside lower net income versus 2023–2024—suggesting growth momentum has softened even though underlying profitability remains elite.

Balance Sheet

The balance sheet is very conservative: total debt is consistently zero and the company is funded primarily by equity. Returns on equity are extremely high (roughly mid-50% to ~70%), reflecting strong earnings power relative to the equity base. A watch-out is that equity and total assets have drifted down in the most recent year (2025 vs. 2024), which could limit balance sheet expansion if the softer top-line trend persists.

Cash Flow

Cash generation is strong and high quality: free cash flow closely tracks net income (near ~1.0 in recent years), indicating profits convert well into cash. Cash flow comfortably covers reported earnings, and free cash flow has generally grown over time, but it declined in 2025 (about -9%) after a strong 2024—mirroring the recent slowdown in revenue and earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	13.12M	13.12M	13.61M	12.82M	11.72M	10.93M
Gross Profit	11.82M	11.92M	12.68M	11.86M	10.87M	9.98M
EBITDA	9.89M	10.17M	10.74M	10.20M	9.42M	8.22M
Net Income	7.58M	7.58M	8.10M	8.37M	7.67M	6.73M
Balance Sheet
Total Assets	12.86M	12.86M	13.73M	13.28M	13.12M	12.91M
Cash, Cash Equivalents and Short-Term Investments	5.08M	5.08M	6.00M	5.72M	6.13M	6.49M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.31M	1.31M	1.73M	1.22M	1.30M	1.09M
Stockholders Equity	11.55M	11.55M	12.00M	12.06M	11.82M	11.82M
Cash Flow
Free Cash Flow	7.20M	7.01M	8.33M	7.89M	7.55M	6.11M
Operating Cash Flow	7.22M	7.03M	8.34M	7.90M	7.56M	6.37M
Investing Cash Flow	-19.19K	173.16K	186.06K	90.51K	-11.76K	-259.83K
Financing Cash Flow	-8.12M	-8.12M	-8.25M	-8.30M	-7.92M	-7.69M

Bioventix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1800.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BVXP, the sentiment is Positive. The current price of 1800 is below the 20-day moving average (MA) of 1813.75, below the 50-day MA of 1843.10, and below the 200-day MA of 2303.41, indicating a neutral trend. The MACD of -4.01 indicates Negative momentum. The RSI at 53.05 is Neutral, neither overbought nor oversold. The STOCH value of 73.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:BVXP.

Bioventix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVXP	75 Outperform	£96.66M	12.73	64.40%	8.33%	-3.61%	-6.35%
APTA	52 Neutral	£23.60M	-6.25	-213.66%	―	39.88%	81.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FAB	44 Neutral	£16.88M	-9.38	-164.37%	―	-11.43%	23.40%
AVCT	42 Neutral	£225.26M	―	―	―	―	―
4BB	41 Neutral	£89.04M	-5.79	-209.34%	―	198.49%	-26.66%
OBD	38 Underperform	£11.80M	-0.29	-407.49%	―	72.17%	79.03%

Bioventix Corporate Events

Bioventix CFO Increases Stake with Share Purchase

Bioventix plc announced that its Chief Financial Officer, Bruce Hiscock, has purchased 150 ordinary shares in the company, reflecting a minor increase in his beneficial interest to 0.03% of the company’s issued share capital. This transaction, conducted on the London Stock Exchange’s AIM market, is in line with the EU Market Abuse Regulation and may indicate confidence in the company’s future prospects.

Bioventix Posts Annual Report and Announces AGM

Bioventix plc has announced the posting of its Annual Report for the year ending June 30, 2025, along with a Notice of Annual General Meeting (AGM) scheduled for December 4, 2025. The report and notice have been sent to shareholders who opted for hard copies and are also available on the company’s website. This announcement is a routine part of Bioventix’s corporate governance, ensuring transparency and engagement with shareholders, and it underscores the company’s commitment to maintaining open communication with its stakeholders.

Bioventix CEO Increases Stake in Company

Bioventix plc announced that its CEO, Peter Harrison, and his wife, Abigail Harrison, have purchased additional shares in the company, increasing their total beneficial interest to approximately 5.8% of the company’s issued share capital. This move indicates a strong vote of confidence from the company’s leadership, potentially impacting investor perceptions and market positioning positively.

Bioventix Chairman Increases Stake in Company

Bioventix plc announced that Ian Nicholson, the Non-Executive Chairman, purchased 500 ordinary shares of the company at a price of 1,865 pence per share. This transaction increases Nicholson’s beneficial interest to 13,500 shares, representing approximately 0.3% of the company’s issued share capital, potentially signaling confidence in the company’s market position and future prospects.

Bioventix CFO Increases Stake with Share Purchase

Bioventix plc announced that Bruce Hiscock, the Chief Financial Officer, purchased 119 ordinary shares of the company at an average price of 2,009 pence per share. This transaction increases Hiscock’s total beneficial interest in the company to 1,324 shares, representing approximately 0.03% of the issued share capital. The purchase, conducted on the London Stock Exchange’s AIM Market, reflects a modest increase in insider ownership, potentially signaling confidence in the company’s future prospects.

Bioventix Faces Revenue Decline Amid Market Challenges

Bioventix reported a decrease in revenue and profit for the year ended June 2025, with revenue down by 4% and profit before tax down by 5%. The company is transitioning towards creating antibodies for neurological conditions, but faces challenges in the Chinese market due to local manufacturing policies and cost reduction pressures. Despite these challenges, sales of their vitamin D antibody increased by 12%, although other product sales faced declines. The company anticipates continued pressure on revenue due to market dynamics and changes in their commercial structure.